of neurological disorders, we summarized the recent experimental results and further discussed the potential improvement of transplanted cell survival after hypoxic preconditioning.
IschemIc condItIons In BraIn dIsorders
Hypoxia or lower oxygen levels might occur in daily life, in different parts of the body, and under a variety of conditions (For example, individuals in mountainous regions can adapt to hypoxia generated by lower oxygen levels at higher elevations, which allow managing to maintain normal physiological functions in plateau residents). In the nervous system, ischemic/hypoxic conditions are more likely to happen after brain disorders as neuronal activities consume a large amount of oxygen and glucose for maintenance of normal brain activities. Embryos and newborns have a significantly higher ability to survive hypoxic and ischemic conditions. It is well known that bone marrow cells survive well in the physiologically hypoxic conditions (1-6% O 2 ) in the bone marrow. In addition, blood oxygen and glucose levels in the brain, or an ischemic event caused by occlusion of blood vessels, could greatly influence cell survival and brain functions. [3, 4] Although decreased energy demands prevail under hypoxic and ischemic conditions as a compensatory response, severe ischemia leads to neuronal cell death and injuries to other systems, such as disruption of the blood-brain barrier due to damage to endothelial cells and the extracellular matrix (ECM). On the other hand, manipulation of hypoxic conditions within the sublethal range in physiological and pathological conditions shows a priming effect of improving the tolerance of cells, tissues, and the whole body to future insults. Translation of hypoxic preconditioning into clinical applications has been an active research area. We summarize the adaptive changes focusing on cellular signaling pathways and gene regulation following hypoxia and hypoxic preconditioning as well as the potential clinical application of preconditioning in cell-based therapies.
neuroBIoLogIcaL etIoLogy of BraIn dIsorders
Neurological disorders are associated with degeneration of neurons and gradual losses of neural functions. Due to the phenotypic heterogeneity, complicated neuronal connectivity, and the multitude of interactions among neurons, astrocytes, microglial cells, oligodendrocytes, and stem/progenitor cells, neurological disorders are often regarded as some of the most complicated disease conditions to decipher and treat. [5] [6] [7] Recent research has identified multiple factors and key mechanisms that regulate distinct cell plasticity, such as cell type-specific differentiation and culture protocols. These specific manipulations of cells (e.g., stem cell-derived/differentiated neurons in vitro) highlight the potential for the treatment of central nervous system (CNS) disorders such as stroke, traumatic brain injury, Parkinson's disease (PD), and Alzheimer's disease (AD). [8] However, there is still a great unmet translational need for improving the disease models and effective translation of therapeutic interventions. So far, much effort has been done to increase the feasibility and efficacy of cell-based therapies. In this review, we highlight the major types of endogenous and exogenous stem cells and discuss the recent progress in cell-based therapy for CNS disorders.
Neural stem cells (NSCs) and neural progenitor cells (NPCs) in the adult brain are mainly located in two regenerative niches: the subventricular zone (SVZ) flanking the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus (DG) in the hippocampus. [9] [10] [11] [12] [13] [14] In rodent models, neurons originating from these two areas have distinct destinies: the neuroblasts derived from the SVZ migrate along the rostral migratory stream, become interneurons, and integrate with other cells in the olfactory bulb. The newborn neurons of the SGZ differentiate and assimilate into the local neural network of the hippocampus where they are involved in learning, memory, and mood regulation.
[14] Interestingly, human SVZ neurogenesis exhibits an evolutionary divergence which shows a remarkable difference from other vertebrates. In humans, it was shown that long-distance migration of SVZ-derived NPCs to the olfactory bulbs is virtually nonexistent, while there is abundant neurogenesis from the SVZ into the adjacent striatum. [15, 16] Neurogenic activities in the SVZ and SGZ may be upregulated following stroke. [17, 18] Endogenous NPCs proliferate after ischemia and differentiate into neuroblasts and astrocytes, which subsequently migrate along the route from the SVZ to the infarct region. [19] [20] [21] Increasing evidence suggests that some factors, such as lipid accumulation, suppress the homeostatic and regenerative functions of NSCs (e.g., perturbation of the microenvironmental fatty acid metabolism in AD impedes neural regeneration [22] ). Accumulating evidence unveils that NPC functions are regulated by different signals, which should be taken into consideration when optimizing cell-based therapies.
[23-27] Identification and modification of inhibitory factors might help to augment the brain's adaptive endogenous regeneration to various neurological disorders and improve stem cell-mediated brain repair.
hyPoxIa and dIseases

Hypoxia and mobilization of endogenous stem cells
The activation of chemokine receptors can increase the number of migrating NPCs (e.g., the CXC chemokine receptor type 4 [CXCR4] , which is the cognate receptor for stromal-derived factor 1 [SDF-1], crucial for coupling neurogenesis with angiogenesis after stroke and directing the migration of neuroblasts to the infarct region [28] ). In addition, C-C chemokine receptor type 2 (CCR2), the cognate receptor for monocyte chemoattractant protein 1, is upregulated in migrating neuroblasts following ischemia and is critical for proper destination targeting. [29] Neurotrophic and growth factors also play important roles in the regulation of adult regeneration, including, but not limited to, granulocyte-colony-stimulating factor (G-CSF), insulin growth factor (IGF-1), glial cell-derived neurotrophic factor (GDNF), and brain-derived neurotrophic factor (BDNF). [30] [31] [32] G-CSF and IGF-1 can reduce NPC death through altering key survival pathways (e.g., the phosphoinositide 3 kinase-Akt pathway). Several recent clinical trials demonstrated the ability of G-CSF to both mobilize endogenous bone marrow cells and exert its neuroprotective effects to promote stroke recovery.
[33] BDNF and noggin, another developmental protein, can actively recruit NPCs to form new medium spiny projection neurons (MSNs) and ameliorate the progressive impairment of motor function and cognition associated with Huntington's disease (HD). [34] In addition to growth factors, anti-inflammatory drugs such as indomethacin, noncoding RNA, and hormones can also increase endogenous NPC proliferation. [35, 36] Together, these studies corroborate the principle that factors that promote neurogenesis might contribute to better cell-based therapies for neurological disorders.
Mobilization of stem cells from the bone marrow also has great therapeutic potential.
[37] Plerixafor (also known as age-related macular degeneration (AMD)-3100, an inhibitor of CXCR4) significantly increased vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2)-positive cells in the peripheral blood, elevated SDF-1 levels, and promoted blood vessel formation in an ischemic flap model. Hypoxia-induced upregulation of CXCR4 has been studied in CD34+ cells and cardiac progenitor cells in vitro and after transplantation (including in utero or intravenously), which resulted in facilitated recruitment of donor CD34+ cells to the heart against ischemia-reperfusion injury.
[38] Co-culture of neurons with SDF-1-secreting olfactory ensheathing cells after oxygen-glucose deprivation (OGD) treatment showed enhanced neurite outgrowth.
[39] G-CSF could mobilize CD34+ hematopoietic stem cells and effective to reduce the microglial responses in the preterm brain following hypoxic-ischemic injury.
[40] Bone morphogenetic protein (BMP), erythropoietin (EPO), G-CSF, and interleukin-10 (IL-10) showed synergistic effects for increasing the homing and differentiation of NSCs and bone marrow mesenchymal stem cells (BMSCs) into the peri-infarct/lesion regions. [41] [42] [43] [44] Fasudil, an inhibitor of Rho kinase, significantly increases cellular G-CSF levels, contributing to NSC mobilization to treat hypoxia/reperfusion injury. Mobilization of intravenously injected endothelial progenitor cells (EPCs) can be induced by shock wave treatment from the peripheral blood to ischemic hind limbs.
[45] In chronic hypoxia secondary to pulmonary hypertension, when migratory adaption to SDF-1 and cell adhesion are significantly inhibited, hypoxic EPCs with upregulated VEGFR-2+/SCA-1+/CXCR-4+ (SCA-1: stem cell antigen 1) seem insufficient to stimulate the remodeling of the vascular network.
[46] Enhancement of EPO/EPOR is demonstrated to attenuate hypoxia-induced pulmonary hypertension, while EPOR (-/-) mice fail in the mobilization of EPCs to pulmonary endothelium and to other tissue after hypoxic-ischemic injury.
[47]
Key mechanisms underlying hypoxia and hypoxic adaptation
Hypoxia-inducible factor 1-alpha (HIF-1α) is a critical mediator in hypoxia and reactive oxygen species (ROS)-induced responses, which is involved in the activation of many cytokines, chemokines, transcription factors, and growth factors in response to hypoxia in almost all kinds of cells. [48, 49] HIF-1α was stabilized to upregulate β-catenin transcription in myelogenous leukemia stem cells. [50] Hypoxic adaptation increases the expression of glucose transporter isoform 3 in the neuro-2A neuroblastoma cells through regulation of the activator protein 1, cAMP response element-binding protein (CREB), HIF-1α, and hypoxia response element. [51] In hypoxia-treated mesenchymal stem cells (MSCs), the glucose-6-phosphate transporter is significantly increased through upregulation of HIF-1α, aryl hydrocarbon receptor (AhR), and AhR nuclear translocator. [52] In a γ-radiation model, HIF-1α expression and activation of mechanistic target of rapamycin (m-TOR) contribute to the development of radio-resistance. [53] Recent investigations suggest a regulatory role of HIF proteins on microRNA (miRNA) expression under hypoxic conditions. HIF-1α can bind to the placental growth factor (PlGF) promoter and regulate the synthesis for miRNA-214 to target PlGF posttranscription regulation in sickle cell disease and cancer. [54] Hypoxia promotes proliferation of BMSCs, and miRNA-210 was reported to be involved in the BMSC proliferation through an interaction with the HIF pathway. [55] Under lethal OGD, BMSCs also show upregulated miRNA-34a, a pro-apoptotic signal molecule which promotes oxidative stress and causes mitochondrial dysfunction through repressing silent-mating-type information regulation 2 homolog 1 and activating forkhead box O3. [56] Significant changes in hydrogen sulfide (H 2 S) and cystathionine γ-lyase (CSE) might occur during OGD. The CSE/H 2 S system has thus been considered a potential target to protect BMSCs against apoptosis in transplantation therapy. In neurons after OGD, DJ-1 proteins (encoded by PARK7) translocate into the mitochondria, where mitigation of oxidative stress may mediate neuroprotection after hypoxia and ischemia. [57] The levels of matrix metalloproteinase (MMP) in the brain after ischemia and in hippocampal slice cultures after OGD are associated with glial activation. MMPs are also migratory factors for stem cells. In humans, hypoxia treatment of CD34+ umbilical cord blood hematopoietic stem cells (UCHSCs) results in the upregulation of cAMP-1-activated exchange protein (Epac-1) and MMPs, facilitating cellular engraftment, migration, and differentiation after transplantation into ischemic brains. [58] MMPs are further subclassified into transmembrane types (MT-1 to MT-3, and MT-5) and glycosylphosphatidylinositol-anchored types (MT-4 and MT-6). When exposed to pro-inflammatory cytokines and hypoxia, the MMP inhibition in BMSCs is mediated by the tissue inhibitor of metalloproteinase 1, which is considered an important mechanism to protect the ECM.
In vivo studies confirmed the decreased myelin density in the white matter after cerebral hypoperfusion [59] [60] [61] (e.g., cilostazol, an activator of cyclic AMP, which reversed the white matter loss and promoted oligodendrocyte differentiation). The neuregulin-1 isotype β-1/ErbB4 signaling was involved in protecting oligodendrocyte progenitor cells (OPCs) during and after a hypoxic event. In hypoxic culturing conditions (3% O 2 ) and methylprednisolone co-treatment, the spinal cord-derived neural progenitors downregulated HIF-1α and the hairy and enhancer of split-1, a downstream Notch signaling mediator. HIF-1α depletion in ES cells showed significant reduction in sex-determining region Y box (SOX)-1 and elevation in BMP-4, supporting the potential mechanism underlying hypoxia-mediated neural commitment and differentiation.
Hypoxic and ischemic preconditioning in vivo
Sublethal ischemia has been demonstrated to be effective for an enhanced tolerance to lethal ischemia in the brain and the heart. Protective effects after hypoxic or ischemic preconditioning involve neural plasticity processes and adaptive responses in the brain. Hypoxia-preconditioned cells and tissue show changes in physiology, neurochemical, and neuroelectrophysical properties. [62] Investigations of sublethal hypoxic pretreatment in vivo as well as in vitro might provide new strategies for the therapy or prevention of CNS disorders and injuries.
Ischemic tolerance in the CNS can be induced by hypoxic preconditioning. In adult animals after fetal tracheal occlusion, the blood pressure could drop to an extremely low level within several minutes, and severe physiological responses might occur. Although respiratory frequency and cardiovascular activity can be regulated to control the oxygen balance, the protective mechanisms after preconditioning hypoxia have been proven to be more than these systemic controls. Repeated autohypoxic models in which animals were placed into sealed chambers have been utilized to study hypoxic tolerance by the measurement of grasping behaviors. [63] Hypoxia, cancer, and cancer stem cells Hypoxia is one of the common players in tumorigenesis and tumor progression. The cancer stem cell niche, recently identified in many types of tumors, demonstrates a hypoxic environment for tumor self-renewal. There is evidence that low ROS conditions contribute to the tumor stemness. [64] Hypoxia in tumors may lead to an elevation of octamer-binding transcription factor 4 (OCT-4), the master pluripotency factor, and one of the cancer cell stemness markers. [65] Kruppel-like factor 4 (KLF-4), NANOG, and OCT-4 increase dedifferentiation and cell resistance to chemotherapeutic agents and hypoxic injury. [66, 67] In pancreatic ductal adenocarcinoma cells, hypoxia can significantly upregulate nestin through transforming growth factor β-1 (TGFβ-1)/mothers against decapentaplegic homolog 4 (SMAD-4) signaling. [68] Hypoxia induces CD24 (a marker for tumor formation and metastasis) through HIF-1α binding to the promoter in many cancers. [69] HIF-1α and the MT-1 MMP signaling has been also identified for oncogenic cell migration. [70] In medulloblastoma cells, hypoxia can stabilize the interactions between HIF-1α and Notch proteins, causing an expansion of CD133+/nestin+ cell subpopulations. [71] In melanoma cells, HIF induction, in response to hypoxia, results in greater melanoma proliferation, migration, and metastasis through SNAIL1 activation and E-cadherin downregulation. [72] Cobalt chloride (CoCl 2 ) exposure (to mimic the effect of hypoxia) activates HIF-1α/pAkt and upregulates genes required for metabolite transport and metabolism in tumor cells (such as glioblastomas). The miRNA regulation may be involved in the maintenance of the cancer stem cell phenotype. [73, 74] One of the HIF-regulating factors, EPO, has been shown to promote tumorigenesis by activating Janus kinase (JAK)/STAT signaling. [75] In Hodgkin and Reed-Sternberg tumor cells, Notch-1 and JAK/STAT pathway are activated, whose inhibition results in apoptosis for treating classical Hodgkin lymphoma. [76] In an experimental glioma model, tumor cells expressed CD133, nestin, VEGF, sodium calcium ex-changers, and showed hybrid cell death after chemotherapy drug treatment. [77, 78] Hypoxia also inhibits HIF-1α degradation, which is BMP dependent. [79] Further studies suggest HIF-1 and VEGF as two angiogenic targets that can be used for diagnosis and blocked for treating cancers. [80] [81] [82] Anthracycline chemotherapy is effective in inhibiting HIF-1, which blocks the mobilization of circulating progenitors to the tumor angiogenesis. [83] stem ceLLs and ceLL theraPy Stem cells are major sources of cell-based therapy [ Figure 1 ]. They can be classified as totipotent cells, naïve pluripotent stem cells, primed pluripotent cells, and tissue-specific multipotent stem cells. Totipotent cells, characteristic of the zygote and early blastomeres, can develop into all tissues, including extra-embryonic tissue. While both naïve and primed pluripotent cells can form a teratoma, the two different pluripotent states have distinct molecular differences. Naïve stem cells are in a ground state, harboring the prerequisite potential to differentiate into all embryonic lineages and develop into chimeric blastocysts. It possesses high clonogenicity and does not carry specification markers. [84] Primed pluripotent cells, which do not produce chimeras, express FGF-5 specification marker and have low clonogenicity. For pluripotency markers, naïve stem cells display greater levels of pluripotency marker proteins, including OCT-4, NANOG, SOX-2, KLF-2, and KLF-4, while primed cells lose KLF-2 and KLF-4 expression. Aside from the naïve and primed pluripotent states, a study discovered an intermediate pluripotent stage between the two states. [85] The tissue-specific multipotent stem cell has the least differentiating potency among all stem cell types, with the ability to form tissue-specific cell types. [86, 87] 
Human embryonic stem cells
The success in generation and culture of ESCs from mice, primates, and human embryos has been considered a milestone of stem cell research. ESCs are a useful tool for exploring early embryonic development, modeling pathological processes of diseases, and developing therapeutics through drug discovery and potential cell replacement. [88] [89] [90] The human ESCs (hESCs) now hold a great promise for regenerative medical treatments as the cells can generate any cell type of the body. The hESCs are mainly defined as primed pluripotent cells, which are different from and show less plasticity than the murine ESCs. It remains unclear whether human-naïve pluripotent stem cells, obtained either by continued transgene expression or through specific chemical manipulation of the culturing microenvironment, are analogous to mouse counterparts. [91] [92] [93] [94] [95] Nevertheless, it is worthwhile to validate the findings from these reports using naïve hESCs generated from different strains and laboratories in future studies.
Differentiation of hESCs in vitro has been achieved at very high efficiencies into various transplantable progenitors/precursors and terminally differentiated neuronal and glial cell types, which include cortical glutamatergic, striatal γ-aminobutyric acid gamma aminobutyric acid-ergic, forebrain cholinergic, midbrain dopaminergic, serotonergic, and spinal motor neurons, as well as astrocytes and oligodendrocytes. [96] [97] [98] [99] [100] [101] [102] These differentiated cells, including neurons, astrocytes, and oligodendrocytes, have been exogenously transplanted and evaluated in animal models. Translation into the clinic is ongoing for various neurological disorders, including: (1) PD, in which nigro-striatal neurons are lost before other neurons, (2) HD, in which MSNs are lost, resulting in striatal atrophy, and (3) glial and myelin disorders. [103] [104] [105] [106] Other disorders, including AD and Lewy body disease, which involve a multitude of neuronal cell types, and amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy, which are multicentric and diffuse neurodegenerative disorders, remain poor targets for stem cell-based therapies. To date, it is widely accepted that glial metabolic deficiencies might contribute to disease progression in ALS, in which neurons might be the paracrine victims of glial dysfunction. As such, cell-based treatment approaches for ALS and other neurodegenerative disorders have thus shifted the focus away from neuronal replacement toward glial replacement. [107] If successful, such studies might herald the application of hESC-derived glia for treating ALS and related disorders.
Induced pluripotent stem cells
The iPSCs are pluripotent cells that are artificially de-differentiated from adult somatic cells by several transcription factors or small-molecule compounds and have ignited the field of lineage reprogramming. [108, 109] There are epigenetic differences between iPSCs and ESCs, which include expressions of unique genetic signatures, teratoma formation capacity, and the differentiation potency and flexibility (e.g., dissimilar differentiation potential into various transplantable neural cells [110] ). Furthermore, compared to ESCs, iPSCs can be more amenable as donor cells for cell replacement therapy, in vitro disease models, and drug screening. [111] [112] [113] First, iPSCs are derived from adult somatic cells, which can be easily obtained from patients, and then banked and stored. Second, cultures of hiPSCs and hESCs are technically similar, but the generation of iPSCs harbors much less ethical concern and opposition. [114] Third, given the somatic cell source and the autologous nature of iPSCs, cell therapy using iPSCs should have no immune rejection in theory, or at least minimize the risk of immune system rejection. However, a recent report suggests that some unusual gene expressions in transplanted cells derived from the iPSCs may trigger an immune response. [115] The miPSCs and hiPSCs provide a powerful tool for developmental biology research and translational medicine. To develop and achieve fast improvement in pharmaceutical agents, iPSCs combined with microfluidic technology have provided bio-screening platforms, allowing for high-throughput preclinical drug screening and advancing the search for new pharmacological therapies. Furthermore, iPSCs allow for greater experimental interrogation and convenience compared to transgenic animal models when determining clinically relevant doses and the short-and long-term adverse effects.
One of the most exciting features of iPSCs is the potential use of reprogrammed somatic cells to establish disease-relevant phenotypes in vitro and to simulate and recapitulate the molecular signatures of pathogenesis in an early stage. This has been implemented in a variety of neurological disorders, such as familial dysautonomia, Rett syndrome, HD, AD, ALS, PD, and schizophrenia. [116] [117] [118] [119] [120] [121] According to the National Institutes of Health (NIH)-established ethical guidelines and standards, the hiPSC repositories of personalized cell lines from patients can be developed and banked, and the iPSC technology can be used to model disease and screen drugs. Genetic modifications or enhancements of patient iPSCs are being tested (e.g., reinfusion treatment for patients with sporadic diseases). Genome editing of hiPSCs uses programmable nucleases including transcription activator-like effector nucleases and clustered regularly interspaced short palindromic repeats Cas9 technology. [122] [123] [124] Genome editing has greatly expanded our vision for understanding of pathological processes by studying cellular/disease models, and human cells and tissue, in which the programmable nucleases can directly correct/introduce genetic mutations. Compared to traditional drug therapy, therapeutic genome editing strategies provide an alternative method to treat both genetic diseases and diseases with genetic and environmental factors, such as hemophilia and severe combined immunodeficiency. [125] A combination therapy with iPSCs and genome editing is proposed as a new therapy to introduce protective mutations, to correct deleterious mutations, to eliminate the antigenic/immunogenic signals in the iPSCs, or to destroy foreign viral DNAs in the human body. [126] In the absence of exogenous template DNA, the programmable nucleases create a double strand break (DSB) in desired regions, but due to the error-prone nonhomologous end joining (NHEJ) mechanism of re-ligation, an insertion/deletion (indel) mutation is frequently created at the DSB site. NHEJ-based genome editing has been tested in several proof-of-concept studies for treating genetic diseases. The reported editing on fibroblast growth factor receptor-3 (FGFR-3) for achondroplasia and dystrophin for Duchenne muscular dystrophy specifically inactivated the mutant allele, corrected the disease mutation, and shut down the expression of pathogenic gene product. [127] Another example was to treat trinucleotide repeat disorders, such as fragile X syndrome and HD. To ablate the triple repeats, a pair of single-guide RNAs was applied to target both sides during the expansion. NHEJ-based genome editing antagonized a viral infection in several proof-of-concept experiments including hepatitis B virus and human immunodeficiency virus. [128] [129] [130] Other than NHEJ, the high-fidelity homology-directed repair (HDR)-based mechanism of genome editing was studied to treat deleterious loss-of-function mutations, such as cystic fibrosis and β-thalassemia. HDR-based genome editing provides an exogenous repair template of a single-stranded oligodeoxynucleotide and a donor plasmid to correct a mutated allele to be wild type. It could also integrate therapeutic transgenes into a genomic safe harbor site.
Mesenchymal stem cells
MSCs derived from the bone marrow, umbilical cord blood, and adipose tissue could exert immunomodulatory and anti-inflammatory effects in CNS disease models such as stroke and MS. [131] The bone marrow-derived MSCs were shown to promote neuronal survival and remove amyloid plaques in a rat AD model. [132] Overexpression of some neurogenic/angiogenic factors such as VEGF in the transplanted MSC cells might help improve memory and induce neovascularization/neurogenesis within the adult brains. Clinical trials demonstrated safety and feasibility of MSC transplantation in acute and chronic stroke with no tumorigenicity reported following cellular transplantation. [133] Fetal neural progenitor cells Fetal NPCs, which can differentiate into functional neurons and multiple types of neuroglia, are an ideal platform to bridge the gap between traditional model systems and human biology. [134] [135] [136] [137] The differentiation of fetal hNPCs in vitro could recapitulate brain development. Recent efforts intending to measure the transcriptome from the fetal human brain provide an unbiased in vivo standard using single-cell approaches and genome-wide transcriptome analyses. [138, 139] The studies suggested that the fetal hNPCs have a stronger matching genomic overlap with the in vivo cortex compared to hiPSCs, allowing for the identification of specific neurodevelopmental processes related to pathophysiology of developmental disorders. Fetal hNPCs were investigated in clinical trials for the treatment of spinal cord injury (SCI) and AMD, but the safety has not yet been verified.
PrecondItIonIng In stem ceLL theraPy
Hypoxia-regulated cell differentiation and regeneration
NSC phenotypes and repair mechanisms have been studied as a regenerative therapy in CNS diseases. Normally, hypoxic conditions and intracellular ROS levels help maintain the proliferation and self-renewal of NSCs in the brain. [140] HIF-1α overexpression can promote NSC proliferation and differentiation after intracerebral hemorrhage and hypoxic/ischemic injury. HIF-1α has been shown to promote the ESC differentiation into dopaminergic neurons. [141] Studies about hippocampal CA1 neurogenesis suggest that the attenuated Notch-1 signaling by an inhibitor of γ-secretase might determine the neuronal lineage differentiation. Leukemia inhibitory factor (LIF) and phosphorylated signal transducer and activator of transcription 3 are dramatically increased after hypoxic-ischemic injury, which activate LIF receptor (LIFR)/glycoprotein (gp130) and Notch-1 for expansion of NSCs in the brain. [142] Metformin, a well-tolerated oral medication, promotes adult neurogenesis through activation of atypical protein kinase C/CREB-binding protein pathway. Preclinical studies using hypoxic-ischemic injury models have shown that treatment using metformin can alleviate sensorimotor defects and reduce ischemia-reperfusion injury. [143, 144] Hypoxia-ischemia has been shown to cause accumulation of HIF-1α and an increase in VEGF/VEGFR in endothelial cells and EPO/EPOR in glial cells. [145] [146] [147] In hypoxic conditions of 3% oxygen, upregulation of angiogenic factors (such as angiotensin II [Ang II], angiotensin-converting enzyme [ACE] , and Ang II receptor Type 1 [AT1R]) and some specification transcriptional factors (such as the SOX-2) was observed. Ang II pretreatment activated the AT1R/HIF-1α/ACE axis in rat BMSCs and promoted VEGF production and the angiogenic response. Co-culturing of stem cells from apical papilla and human umbilical venous endothelial cells resulted in the formation of endothelial tubules, which was bolstered by hypoxic conditions. [148] Involvement of miRNA-31 and miRNA-720 in vascularization by EPCs was also reported in coronary artery disease, and this phenomenon was directed by HIF-1α signaling.
Glial progenitor cells in the SVZ and the white matter are activated and expanded after ischemia, and this can be further augmented by treatments, including uridine diphosphoglucose glucose, GDNF, epidermal growth factor, EPO, or memantine to differentiate into oligodendrocytes. [149, 150] Hypoxic-ischemic brain injury in neonates induces cell death in committed neural precursors but stimulates the proliferation and differentiation of immature neural progenitors for brain repairs. [151] Transplantation of stem cells such as UCBMCs might promote the proliferation and neuronal differentiation of endogenous NSCs. Neurogenin-1 upregulation and BMP-4 downregulation have been identified as putative mediators of these activities. [152] Hypoxia-ischemia induces repair mechanisms of endogenous stem cells, and more recently identified, stemness of resident cells via reprogramming. [153] In MSCs, hypoxia regulates miRNA-302, which supports their reprogramming into pluripotent states. The combination of hypoxia and fibroblast growth factor 2 (FGF-2) together induces the expression of OCT-4 and NANOG in L87 cells and primary MSCs. [154] After inhibition by FGF-2, the proliferation of human MSCs is inhibited, leading to an osteogenic or an adipogenic differentiation. [155] In 2% oxygen conditions and ECM adhesion, viability and multi-potentiality can be preserved in transplantation therapy. In slice culture models, hypoxic preexposure will markedly reduce the survival of seeded stem cells on the slices. Methylprednisolone, a widely used glucocorticoid or corticosteroid drug, inhibits the endogenous brain repair mechanisms after treating SCI through changing a variety of growth and angiogenic factors. [156] Maintaining NSC renewal by drug-inducing Notch-1, OCT-4, and SOX-2 expressions may promote regeneration after SCI. [157] Differentiation and survival of progenitor/stem cells might also be affected in hypoxic, starvation, and ischemic conditions. An ischemic insult to the cortex can markedly increase the expression of SDF-1 in the ischemic region, which is a chemoattractant for directional migration of neuroblasts expressing CXCR-4. [158] Hypoxia can induce migration in various types of cells, including BMSCs, cardiac SCA-1+ progenitors, ESCs/iPSCs, NSCs, and many tumor cells. [159] [160] [161] [162] [163] The SDF-1/CXCR4 axis and hypoxia are mediators for BMSC/EPC migration in the bone marrow, the peripheral blood, and many other organs. [83, 164, 165] Upon hypoxic stimuli, IL-8 is upregulated and activated in acute myeloid leukemia immune cells, which show greater migration out of the stem cell niche. [166] 
Transplantation of stem cells
Stem cell transplantation holds a great promise for vascular diseases and many other degenerative disorders. [167] [168] [169] As a therapeutic goal for cell transplantation, stimulated angiogenesis ameliorates hypoxia and provides nutrient support, which might help functional recovery through regenerative mechanisms. Transplantation of BMSCs in the acute phase exerts neuroprotective benefits after ischemia. Our group and others demonstrated that hypoxic-preconditioned BMSCs and neural progenitors showed significant increases in the survival of transplanted cells, homing to the lesion sites, neuronal differentiation, and functional benefits after stroke.
[42, 159, 163, 170] Multiple cellular and molecular mechanisms and the beneficial effects of transplantation of hypoxic-preconditioned cells were summarized in previous reviews [2, 171] [ Figure 2 ]. More recently shown in different animal models, hypoxic preconditioning combined with IL-7 overexpression in rat BMSCs was shown to increase the migration capacity and fusion potential with renal epithelial cells. [172] Hypoxic preconditioning might also combine with other anti-apoptotic/oxidative stress pretreatment on MSCs to show greater fusion with host cells and regenerating capacity after ischemia or for treating diabetes and cardiovascular diseases. Recent studies have attempted to use conditioned medium from OGD-treated neurons to precondition human UCMSCs, showing greater pro-angiogenic effects. [173] Conditioned medium from UCMSCs subjected to hypoxia could further enhance mitogenic activity of cardiac SCA-1+ progenitors, indicating a paracrine mechanism. [174] Hypoxia-treated hMSCs contain an enriched secretome of trophic factors which might provide a suitable preconditioning strategy for enhanced differentiation of NPCs after transplantation. [175] Transplantation of BMSCs engineered with miRNA-377 along with direct repression of VEGF transcription showed significantly reduced vessel density and increased fibrosis in the infarcted myocardium. [176] Delivery of saphenous vein-derived pericyte progenitor cells in myocardial infarction models demonstrates a novel role of miRNA-132 in paracrine activation by targeting Ras-GTPase-activating protein and methyl-CpG-binding protein 2. [177] Stem cells cultured in hypoxic conditions show enhanced differentiation potential. Compared to 20% oxygen in vitro conditions, vascularization by the adipose-derived stromal stem cells (ASCs) was significantly decreased in moderate (2% oxygen) and severe (0.2% oxygen) hypoxia conditions. [178] Interestingly, this in vitro test showed an unchanged level of VEGF, indicating an independent pathway for the angiogenesis control. [178] Another group showed that severe hypoxia (0.2% oxygen) dramatically increased both transcriptional and translational levels of VEGF-A and Ang in ASCs. [179] Released VEGF-A was an apoptosis inhibitor of vascular smooth muscle cells controlled by TGF-β/SMAD-3.
[179] Sublethal CoCl 2 treatment on OPC induced a chemical hypoxic stress and suppressed the oligodendroglial differentiation. [180] CoCl 2 (0.5 mmol/L) also increased Eph family receptor-interacting protein B2 (ephrin B2), HIF-1α, and VEGF.
As a means of improving survival and oxidative resistance of BMSCs for transplantation therapy, chemical preconditioning (e.g., H 2 S, LPA, MIF, and pitavastatin) has been suggested. [170, 181] A three-dimensional culture of cardiac SCA-1+ progenitors showed improved cell survival under hydrogen peroxide and anoxia/reoxygenation in the ischemic heart after transplantation. [182] An elevation of Sonic hedgehog, Wnt, and BDNF signaling in the SVZ or transplanted cells may promote the regenerative processes of neural progenitors in hypoxic-ischemic injury models. [183, 184] Following adipose stem cell transplantation, animals housed in an environment allowing voluntary physical exercises showed even better functional recovery after hypoxic-ischemic brain injury. [185] Co-treatment of rat BMSCs with laminin micro-carriers releasing angiogenic VEGF shows some synergistic effects, including angiogenesis and enhanced immature neuron migration toward ischemic core regions. [186] Combination therapy using viral VEGF overexpression and BMSCs might result in the smallest size of infarct and the best functional recovery. Many other growth factors (FGF, GDF-5, IGF-1, and TGF-β) have been suggested for combination therapy with cell transplantation to treat intervertebral disc degeneration and enhancing nucleus pulposus-like differentiation of MSCs. [187] concLusIons Stem cell research has made a rapid progress and great hope for treating a wide spectrum of neurological disorders. Expansion of the repertoire of available stem cell subtypes and an increased understanding of their differentiation potency bring us one step closer toward clinical translation. Furthermore, stem cell models provide far-reaching applications for translational medicine studies, including in vitro disease models to elucidate developmental and pathological mechanisms. Exogenous stem cells and NPCs investigated for treating neurological disorders originate from a variety of sources, including ESCs derived from the inner mass of blastocysts, iPSCs reprogrammed from somatic cells, MSCs, or even adult NS/NPCs. [188] In addition, a combination of hESCs and hiPSCs with gene-editing technologies might provide enhanced cell replacement, trophic support, drug delivery, and immunomodulatory and anti-inflammatory effects. Many clinical trials are under way. Transplantation of lineage-committed cells and the control in the quality and number of transplanted cells have eliminated the risk of tumorigenesis. Efforts are still needed to detect and eliminate cancer stem cells and continuously prevent tumor formation. Another concern is that the cells after transplantation might trigger transplant rejection by the immune system in the long term. This concern is partially resolved now by utilizing autologous iPSCs reprogrammed from the host's own somatic cells. Increasing evidence also suggests that MSCs are low immunogenicity cells and show immunosuppressing effects after transplantation. [189] Other issues include optimization of the transplantation window and anatomic site, as well as generation of pure and specific differentiated cells. Hypoxic and ischemic models have been widely used in the research and development of new drugs and clinical therapy. Preconditioning benefits are induced by an adaptation after a sublethal stimulus and an enhanced resistance to the lethal injury, with many survival and regenerative genes involved. Among them, the upstream signaling mediators, especially HIF-1α, might have a great potential as targets for drug development for neuroprotection and neuroregeneration. Transplantation of hypoxia-preconditioned cells appears to be the first feasible strategy to take the advantage of hypoxic tolerance in clinical applications. Furthermore, preconditioning treatments on remote tissues or organs (remote preconditioning) demonstrate great therapeutic efficacy with a high translational potential. While they both serve therapeutic purposes individually, hypoxic preconditioning and stem cell therapy display tremendous synergistic effects together that warrant further preclinical and eventually clinical studies. 
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